Tandem Diabetes Care, Inc. announced an agreement with Abbott to develop and commercialize integrated diabetes solutions. This partnership will combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems. The collaboration aims to provide more options for people to manage their diabetes, enhancing the capabilities of automated insulin delivery.
Abbott's sensor, currently under development, is designed to combine glucose and ketone sensing technology. The goal is to help individuals living with diabetes detect early ketone rise, which can be critical in avoiding life-threatening diabetic ketoacidosis. This integration has the potential to empower users with faster, more informed actions to protect their health and improve outcomes.
This agreement signifies a continued partnership with Abbott and a commitment to bringing new integrations to customers in the future. The development of a dual glucose-ketone sensor integrated with Tandem's pumps represents a significant advancement in diabetes management technology, offering enhanced safety and proactive care.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.